Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

Bacteriophages could be crucial weapons in the fight against antibiotic-resistant bacteria.

The State of Phage Therapy 

Adagene has announced SAFEbody multi-target collaboration with Sanofi for novel masked immuno-oncology antibody candidates.

Adagene Announces Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates

AbbVie has acquired Syndesi Therapeutics, expanding AbbVie’s neuroscience portfolio.

AbbVie Acquires Syndesi Therapeutics

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Borrowing is good, but invention is best.

Characterizing the Unseen Drama of Analytics

AstraZeneca and Neuroimmune have closed an exclusive global collaboration and license agreement to develop and commercialize NI006.

AstraZeneca and Neurimmune Collaborate on Treatment for Transthyretin Amyloid Cardiomyopathy

Eli Lilly and Company are investing $700 million into a Boston-based facility for the newly announced Institute for Genetic Medicine.

Lilly Launches Institute for Genetic Medicine and Invests in Boston Seaport Site

Alvea has begun preclinical testing of a scalable, shelf-stable DNA vaccine against SARS-CoV-2 variants.

Alvea to Develop New DNA Vaccine Against SARS-CoV-2 Variants

Noema Pharma announces first patient dosed in its Phase IIb clinical trial of mGluR5 inhibitor NOE-101 in trigeminal neuralgia.

Noema Pharma Announces First Patient Dosed in Study Evaluating Efficacy of NOE-101 for Trigeminal Neuralgia

ImmunoGen and Eli Lilly and Company have entered into an agreement that gives Lilly exclusive rights to research, develop, and commercialize ADCs designed for targets selected by Lilly from ImmunoGen’s camptothecin technology.

ImmunoGen Grants Lilly Exclusive Research, Development, and Commercialization License in $1.7+ Billion ADC Deal

Meg Rivers is the former senior editor for 

Podcasts

In this episode of the Drug Solutions Podcast, Chris Spivey, editorial director, and Meg Rivers, senior editor, interview Sean Tucker, PhD, chief scientific officer of Vaxart, on developing oral recombinant vaccines.

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development